Calcium channel blockers versus other classes of drugs for hypertension
J Zhu, N Chen, M Zhou, J Guo, C Zhu… - Cochrane Database …, 2021 - cochranelibrary.com
J Zhu, N Chen, M Zhou, J Guo, C Zhu, J Zhou, M Ma, L He
Cochrane Database of Systematic Reviews, 2021•cochranelibrary.comBackground This is the first update of a review published in 2010. While calcium channel
blockers (CCBs) are often recommended as a first‐line drug to treat hypertension, the effect
of CCBs on the prevention of cardiovascular events, as compared with other
antihypertensive drug classes, is still debated. Objectives To determine whether CCBs used
as first‐line therapy for hypertension are different from other classes of antihypertensive
drugs in reducing the incidence of major adverse cardiovascular events.
blockers (CCBs) are often recommended as a first‐line drug to treat hypertension, the effect
of CCBs on the prevention of cardiovascular events, as compared with other
antihypertensive drug classes, is still debated. Objectives To determine whether CCBs used
as first‐line therapy for hypertension are different from other classes of antihypertensive
drugs in reducing the incidence of major adverse cardiovascular events.
Background
This is the first update of a review published in 2010. While calcium channel blockers (CCBs) are often recommended as a first‐line drug to treat hypertension, the effect of CCBs on the prevention of cardiovascular events, as compared with other antihypertensive drug classes, is still debated.
Objectives
To determine whether CCBs used as first‐line therapy for hypertension are different from other classes of antihypertensive drugs in reducing the incidence of major adverse cardiovascular events.
cochranelibrary.com